Showing Results for
- Academic Journals (55)
Search Results
- 55
Academic Journals
- 55
-
From:Canadian Urological Association Journal (Vol. 8, Issue 7-8Suppl5) Peer-ReviewedAuthor(s): Angela M. Cheung, MD, PhD, FRCPC, CCD Introduction Osteoporotic fractures are common in men, particularly in men undergoing androgen deprivation therapy (ADT) for prostate cancer treatment. As outcomes...
-
From:Biology and Medicine (Vol. 9, Issue 4) Peer-ReviewedAbstract Bone strength is determined by bone mineral density (BMD) and bone quality. Bone fractures are serious adverse events in men receiving androgen deprivation therapy (ADT) for prostate cancer. Although it is...
-
From:PLoS ONE (Vol. 17, Issue 1) Peer-ReviewedObjective To compare the effects of an exercise and dietary intervention with those of standard-of-care management upon change in lift and carry performance and mobility-related self-efficacy beliefs and explore...
-
From:Indian Journal of Cancer (Vol. 55, Issue 2) Peer-ReviewedByline: Prabhjot. Singh, Tapan. Agrawal, Siddharth. Yadav, Brusabhanu. Nayak, Amlesh. Seth, Prem. Dogra INTRODUCTION: Androgen deprivation therapy (ADT) is known to adversely affect the quality of life (QoL). One may...
-
From:Canadian Urological Association Journal (Vol. 11, Issue 6) Peer-ReviewedThe paper by Shayegan et al in this issue of CUAJ represents an important initial step in establishing recommendations for hormonal monitoring in men with prostate cancer on androgen-deprivation therapy (ADT). As...
-
From:Oncology (Vol. 28, Issue 10) Peer-ReviewedPRO Medical or surgical castration (also termed androgen deprivation therapy [ADT]) has been the mainstay of therapy for men with newly diagnosed metastatic prostate cancer. However, with the exception of the potential...
-
From:Stem Cell Research & Therapy (Vol. 9, Issue 1) Peer-ReviewedBackground Androgen deprivation (AD) as the first-line treatment for advanced prostate cancer (PCa) is insufficient for a long-term effect. Castration resistance remains the greatest obstacle in PCa clinical therapy....
-
From:Canadian Urological Association Journal (Vol. 10, Issue 9-10) Peer-ReviewedIntroduction: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is...
-
From:PLoS ONE (Vol. 16, Issue 3) Peer-ReviewedIntroduction To determine the prognostic significance of long-term adjuvant androgen deprivation therapy (A-ADT) over 1 year in achieving undetectable levels of prostate-specific antigen (PSA) less than 0.001 ng/mL in...
-
From:PLoS ONE (Vol. 13, Issue 5) Peer-ReviewedPurpose Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with...
-
From:Immunotherapy (Vol. 5, Issue 11) Peer-ReviewedAuthor(s): Raymond A Clarke [*] 1 , Barry J Allen 2 KEYWORDS : [alpha]-therapy; actinium; adjuvant therapy; alpharadin; bismuth; prostate cancer therapy; PSMA; radioimmunotherapy; TAT Prostatectomy and...
-
From:PLoS ONE (Vol. 17, Issue 10) Peer-ReviewedBackground The treatment landscape for men with metastatic hormone-naïve prostate cancer (mHNPC) has dramatically changed with the approval of next-generation anti-androgen drugs. We compared the treatment efficacy of...
-
From:Canadian Urological Association Journal (Vol. 9, Issue 4) Peer-ReviewedUntil recently, the urologist's active involvement in the care of a patient with advanced prostate cancer is confined to the administration of androgen deprivation therapy (ADT). With the development of castration...
-
From:Oncology (Vol. 32, Issue 11) Peer-ReviewedAs the world population ages, we can expect to care for an increasing number of older cancer patients. Prostate cancer is inherently a condition that affects patients of advanced age. In caring for these patients who...
-
From:Urologic Nursing (Vol. 36, Issue 4) Peer-ReviewedTo the editor: In their article, "Skeletal Health Part 1: Overview of Bone Health and Management in the Cancer Setting," Turner et al. (2016) describe the potential risks to skeletal health arising from the use of...
-
From:PLoS ONE (Vol. 13, Issue 12) Peer-ReviewedObjectives Although estrogenic modulation of serum urate levels is well-known, the androgenic effect on urate homeostasis remains controversial. We investigated the effect of androgen deprivation therapy (ADT) on...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 36, Issue 1) Peer-ReviewedBackground GPRC6A is implicated in the pathogenesis of prostate cancer, but its role remains uncertain because of a purported tolerant gene variant created by substitution of a K..Y polymorphism in the 3rd...
-
From:Canadian Urological Association Journal (Vol. 8, Issue 7-8Suppl4) Peer-ReviewedAuthor(s): Neil E. Fleshner, MPH, MD, FRCSC Although the use of androgen deprivation has been with us for over 60 years, we continue to learn more and more about the androgen axis, how best to suppress it, and how to...
-
From:PLoS ONE (Vol. 12, Issue 2) Peer-ReviewedObjective Androgen deprivation therapy (ADT) increases fracture risk in men with carcinoma of the prostate, but little is known about the fracture risk for different types of ADT. We studied the fracture risk amongst...
-
From:Diabetes (Vol. 62, Issue 2) Peer-ReviewedClinical investigations highlight the increased incidence of metabolic syndrome in prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT). Studies using global androgen receptor (AR) knockout mice...